Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Shares Outstanding (Weighted Average) (2016 - 2025)

IGC Pharma (IGC) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $86.8 million as the latest value for Q3 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 16.59% to $86.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $86.8 million through Sep 2025, up 16.59% year-over-year, with the annual reading at $76.5 million for FY2025, 30.04% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $86.8 million at IGC Pharma, up from $83.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $86.8 million in Q3 2025, with the low at $42.0 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $60.5 million, with a median of $53.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 2.83% in 2023, then skyrocketed 37.18% in 2024.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $49.6 million in 2021, then grew by 5.58% to $52.4 million in 2022, then rose by 21.58% to $63.7 million in 2023, then rose by 21.82% to $77.6 million in 2024, then rose by 11.76% to $86.8 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $86.8 million, $83.0 million, and $76.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.